Dataset Information


BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

ABSTRACT: Tumor cells have unstable genomes relative to non-tumor cells. Decreased DNA integrity resulting from tumor cell instability is important in generating favorable therapeutic indices, and intact DNA repair mediates resistance to therapy. Targeting DNA repair to promote the action of anti-cancer agents is therefore an attractive therapeutic strategy. BRCA2 is involved in homologous recombination repair. BRCA2 defects increase cancer risk but, paradoxically, cancer patients with BRCA2 mutations have better survival rates. We queried TCGA data and found that BRCA2 alterations led to increased survival in patients with ovarian and endometrial cancer. We developed a BRCA2-targeting second-generation antisense oligonucleotide (ASO), which sensitized human lung, ovarian, and breast cancer cells to cisplatin by as much as 60%. BRCA2 ASO treatment overcame acquired cisplatin resistance in head and neck cancer cells, but induced minimal cisplatin sensitivity in non-tumor cells. BRCA2 ASO plus cisplatin reduced respiration as an early event preceding cell death, concurrent with increased glucose uptake without a difference in glycolysis. BRCA2 ASO and cisplatin decreased metastatic frequency in vivo by 77%. These results implicate BRCA2 as a regulator of metastatic frequency and cellular metabolic response following cisplatin treatment. BRCA2 ASO, in combination with cisplatin, is a potential therapeutic anti-cancer agent.

SUBMITTER: Rytelewski M 

PROVIDER: S-EPMC5528603 | BioStudies | 2014-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3496826 | BioStudies
2013-01-01 | S-EPMC3615817 | BioStudies
1000-01-01 | S-EPMC4358401 | BioStudies
1000-01-01 | S-EPMC6158596 | BioStudies
2020-01-01 | S-EPMC7519908 | BioStudies
2012-01-01 | S-EPMC3463227 | BioStudies
2017-01-01 | S-EPMC5618936 | BioStudies
2015-01-01 | S-EPMC4502709 | BioStudies
2016-01-01 | S-EPMC4964088 | BioStudies
2012-01-01 | S-EPMC3806629 | BioStudies